CRISPR Therapeutics vs MiniMed Group

CRISPR Therapeutics (CRSP), health care, and MiniMed Group (MMED), health care, side by side on market value, valuation, margins, balance sheet and price change. Higher and lower are marked; neither is called better.

MiniMed Group is worth $5B on the stock market and CRISPR Therapeutics $3.9B: MiniMed Group is valued at 28% more. CRISPR Therapeutics's operating margin in its latest fiscal year was -18934% and MiniMed Group's -6.13%. Over the past year CRISPR Therapeutics's share price has moved -24.5% and MiniMed Group's +0.87%.

Key facts

CRISPR Therapeutics market value
$3.9B
MiniMed Group market value
$5B
CRISPR Therapeutics revenue
$3.5MFY to 2025-12-31
MiniMed Group revenue
$3.1BFY to 2026-04-24
Superinvestors holding both
0

Market values as of .

CRISPR Therapeutics vs MiniMed Group: every measure side by side
Measure CRISPR Therapeutics MiniMed Group
SectorHealth CareHealth Care
Country Switzerland United States
Fiscal year ends2025-12-312026-04-24
Size
Market cap$3.9Blower$5Bhigher
Revenue$3.5Mlower$3.1Bhigher
Earnings-$581.6Mlower-$333Mhigher
Employees—8,000
Total assets$2.3Blower$4.6Bhigher
Valuation
P/E——
P/S1110higher1.6lower
P/B—1.4
Dividend yield—0.00%
Profitability
Operating margin-18934%lower-6.13%higher
Balance sheet
Net assets$1.9Blower$3.6Bhigher
Total liabilities$343.4Mlower$1Bhigher
Total debt——
Cash on hand$347.6Mhigher$298Mlower
Price change
Today-0.54%higher-4.66%lower
1 year-24.5%lower+0.87%higher

Market value, P/E, P/B, dividend yield and price changes are from live quotes (Yahoo Finance; prices may be delayed 15 minutes or more). Revenue, earnings, operating margin and the balance-sheet figures are from each company's latest annual report filed with the SEC (collected 2026-11-12); a company that reports in another currency is converted to US dollars at the exchange rate of that day. P/S sets today's market value against the latest fiscal year's revenue. “Higher” and “lower” compare the two numbers only; a higher P/E or more debt is not better. Dividend yield and P/B are shown only for companies based in the US. A dash means no figure is on file.

Loading the one-year price chart…

Which superinvestors hold them

From each tracked investor's latest 13F filing. A 13F lists long positions in US-listed shares at a quarter end, filed up to 45 days later.

Both (0)

None of the tracked investors.

CRISPR Therapeutics only (1)

MiniMed Group only (0)

None of the tracked investors.

Percentages are each holding's share of that investor's reported portfolio. Who owns CRSP

Further comparisons

Learn

Questions and answers

Which is bigger, CRISPR Therapeutics or MiniMed Group?

By market value, MiniMed Group is the larger: $5B against $3.9B for CRISPR Therapeutics. By revenue in its latest fiscal year, MiniMed Group is the larger: $3.1B against $3.5M for CRISPR Therapeutics.

Which has the higher operating margin?

MiniMed Group: -6.13%, against -18934% for CRISPR Therapeutics. Operating margin is operating income as a share of revenue in the latest fiscal year.

Which superinvestors own both CRISPR Therapeutics and MiniMed Group?

None of the tracked superinvestors holds both in their latest 13F filing. 1 holds CRISPR Therapeutics and 0 hold MiniMed Group.

Cite this page

Funkfolio, “CRISPR Therapeutics vs MiniMed Group”, data as of 18 November 2026. https://funkfolio.com/compare/crsp-vs-mmed

Underlying data: Yahoo Finance quotes; SEC annual reports collected 2026-11-12; 13F filings.